Skip to content

Net margin at other companies

Eli Lilly logo
Eli LillyLLY
35%+12.3pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
35.5%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-597%-194pp
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-13,856.5%-15,058pp
Beam Therapeutics logo
Beam TherapeuticsBEAM
-742.7%
Regenxbio logo
RegenxbioRGNX
-330.2%-588pp

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Calculated from Prime Medicine’s reported figures.

Based on trailing twelve months.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's net margin?
Prime Medicine (PRME) reported net margin of -4,342.4% in Q4 2025.
How has Prime Medicine's net margin changed year-over-year?
Prime Medicine's net margin increased by 33.9% year-over-year, from -6,566.6% to -4,342.4%.
What is the long-term trend for Prime Medicine's net margin?
Over 2 years (2020 to 2025), Prime Medicine's net margin has grown at a 714.5% compound annual growth rate (CAGR), from -65.5% to -4,342.4%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.